FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

Published:2007-10 Issue:5 Volume:74 Page:307-316
ISSN:0361-9230
Container-title:Brain Research Bulletin
language:en
Short-container-title:Brain Research Bulletin

Author:

Balatoni Balázs,Storch Maria K.,Swoboda Eva-M.,Schönborn Vinzenz,Koziel Agnieszka,Lambrou George N.,Hiestand Peter C.,Weissert Robert,Foster Carolyn A.

Publisher

Elsevier BV

Subject

General Neuroscience

Reference59 articles.

1. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis;Aboul-Enein;Acta Neuropathol.,2006

2. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat;Adelmann;J. Neuroimmunol.,1995

3. Pharmacologic and physiologic influences affecting sensory evoked potentials: implications for perioperative monitoring;Banoub;Anesthesiology,2003

4. Visual evoked potentials in experimental allergic encephalomyelitis;Bilbool;J. Neurol. Sci.,1983

5. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases;Billich;J. Biol. Chem.,2003

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysophospholipid receptors in neurodegeneration and neuroprotection;Exploration of Neuroprotective Therapy;2024-08-22

2. Hallmarks of spinal cord pathology in multiple sclerosis;Journal of the Neurological Sciences;2024-01

3. Fingolimod Administration Following Hypoxia Induced Neonatal Seizure Can Restore Impaired Long-term Potentiation and Memory Performance in Adult Rats;Neuroscience;2023-05

4. Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination;Clinical & Translational Immunology;2023-01

5. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03